Navigation Links
Agendia Appoints Dr. Neil M. Barth MD, FACP, as Chief Medical Officer
Date:1/25/2013

IRVINE, Calif. and AMSTERDAM, Jan. 25, 2013 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced the addition of Dr. Neil M. Barth as its Chief Medical Officer.  In this role, Dr. Barth will translate complex laboratory science and personalized medicine diagnostics into actionable, patient centered solutions for clinicians. 

Dr. Barth is a highly skilled physician with 35 years of collective experience with innovative care delivery and genomic biomarker development.  His tenure of leadership at Hoag Hospital, in Newport Beach, CA provided him a rich opportunity to lead a medical staff of 1,400 physicians and 4,400 nurses.  With a strong background in the basic sciences, health informatics, clinical and regulatory standards, combined with the requisite business acumen, Dr. Barth has been at the forefront transforming the practice and business of medicine in several key areas.  Dr. Barth is board certified in Internal Medicine, Hematology and Medical Oncology. In addition to his medical background, he is a prolific author and co-author and a noted speaker, facilitator, moderator and presenter for a vast array of healthcare management and clinical forums.

"As we enter our next phase of expansion, we are thrilled to add Dr. Barth to our executive team," said David Macdonald , Agendia's Chief Executive Officer. "Dr. Barth's wealth of experience will guide our efforts as we continue to develop Agendia's rich product pipeline to answer key clinical questions for physicians."

About Agendia:
Agendia is a leading molecular diagnostic company that develops and markets FFPE-based genomic diagnostic products, which help support physicians with their complex treatment decisions. Agendia's breast cancer Symphony™ suite was developed using unbiased gene selection, analyzing the complete human genome, ensuring 100% definitive results for cancer patients.  Symphony includes MammaPrint, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, as well as BluePrint­­, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 expression assay, and TheraPrint®, an alternative therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo, hormonal, or combination therapy, and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods.

In addition to the Symphony suite of tests, Agendia has a rich pipeline of genomic products in development. The Company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials.  For more information, please visit www.agendia.com.


'/>"/>
SOURCE Agendia
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Agendia Announces Nine Studies in Breast and Colon Cancer for Presentation at 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO)
2. Agendia Names Industry Veteran Glen Fredenberg CFO and Vice President of Finance
3. Agendia Earns ISO Certification for Facilities in Amsterdam and Irvine
4. Agendia Brings Together Thought Leaders in Molecular Diagnostics and Medical Oncology
5. Agendia Announces Five Studies in Breast Cancer for Presentation at the American Society of Clinical Oncology 2012 Breast Cancer Symposium
6. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
7. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
8. Nephros Appoints John C. Houghton as President and Chief Executive Officer
9. Elsevier Appoints New President of Elsevier CPM Resource Center
10. GenWay Biotech Appoints New Vice President of Custom/OEM
11. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2020)... ... February 19, 2020 , ... Today, Georgetown ... facility rehospitalization rate are the lowest in the company’s history. , Georgetown ... drop year over year. GHC’s skilled nursing facility (SNF) rehospitalization rate was 0 ...
(Date:2/19/2020)... ... February 19, 2020 , ... ... the best colleges and universities for people with disabilities. , The Edvocate ... people with disabilities succeed in higher education. AIC placed in the top ten ...
(Date:2/15/2020)... , ... February 14, 2020 , ... Clean the World, ... sustainability, announced today that its full-service customer portal for hospitality partners has enabled them ... by 52% in 2019. This has allowed Clean the World to produce 5.8 million ...
Breaking Medicine Technology:
(Date:2/21/2020)... ... , ... Representatives with Bay-Bay Water today announced that the company has launched a ... logo as part of the ongoing evolution of our company’s brand,” said Osmay Gonzalez, spokesperson ... is expanding its national reach. , “We have refreshed our logo to reflect who we ...
(Date:2/21/2020)... ... February 21, 2020 , ... Isagenix ... has announced its third and final round of Canada finalists for its annual ... John Birr of Markdale, Ontario; Taiya Farrell of Winnipeg, Manitoba; Véronique Collin of ...
(Date:2/20/2020)... , ... February 20, 2020 , ... ... has a new release with next generation API integration functionality which enables ... VisitorsCoverage Inc. in 2017, TMQuotes was the first white label software-as-a-service ...
(Date:2/19/2020)... MIAMI (PRWEB) , ... February 19, 2020 , ... ... to the film industry. While he is most known for his acting abilities ... exceptional host on the educational show “Behind The Scenes” with Laurence Fishburne. “Behind ...
(Date:2/19/2020)... ... 19, 2020 , ... Nvision Biomedical Technologies , a ... for lower extremities at the American College of Foot and Ankle Surgeons Annual ... Ti Stand-Alone Osteotomy Wedge Fixation System will lead Nvision's innovative showcase. The Trigon ...
Breaking Medicine News(10 mins):